Menatetrenone
From Wikipedia, the free encyclopedia
 |
|
|
Menatetrenone
|
|
| Systematic (IUPAC) name | |
| 3-methyl-2-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca- 2,6,10,14-tetraenyl]naphthalene-1,4-dione |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C31H40O2 |
| Mol. mass | 444.648 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Menatetrenone (INN) is a menaquinone compound used as a hemostatic agent and as adjunctive therapy for the pain of osteoporosis. It is marketed for the latter indication in Japan by Eisai Co., under the trade name Glakay.
[edit] See also
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
